Abstract
This review assesses the latest evidence and guidelines related to the use of aspirin for primary prevention among patients with Type 2 diabetes (T2D) without overt cardiovascular disease. The global burden of T2D is steadily increasing and most deaths among patients with T2D are attributed to cardiovascular events. Furthermore, several haemostatic abnormalities have been shown in this group of patients, including increased platelet turnover and aggregation.
Bidragets oversatte titel | Acetylsalicylic acid for primary prevention of cardiovascular events in patients with Type 2 diabetes mellitus |
---|---|
Originalsprog | Dansk |
Artikelnummer | V03190205 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 181 |
Udgave nummer | 41 |
ISSN | 0041-5782 |
Status | Udgivet - 2019 |